What Roseman Bioventures could change for biotech, medtech, and medical device startups in Nevada
Roseman Bioventures launches in Las Vegas to accelerate biotech commercialization in Nevada. Read what this could mean for startups and the region.
Medical Devices & Diagnostics
Pharma & Biotech
Can Sarepta Therapeutics prove RNA interference works in FSHD1 and DM1 with early Phase 1/2 data
Read why Sarepta Therapeutics’ first siRNA data in FSHD1 and DM1 could matter for rare disease drug development and investor sentiment.
Pharma & Biotech
Ferring wins ADSTILADRIN label update as operational efficiency becomes a bigger oncology battleground
FDA clears faster ADSTILADRIN thawing for bladder cancer care. Read why this workflow update could matter for NMIBC adoption and treatment strategy.
Medical Devices & Diagnostics
What Viz.ai’s latest hypertrophic cardiomyopathy studies reveal about the future of cardiac AI
Viz.ai’s new HCM studies suggest AI-ECG could improve detection and follow-up. Read what this changes for cardiology workflows and adoption.
Pharma & Biotech
One-time gene therapy approach from Ocugen gains traction in dry AMD pipeline race
Ocugen reports positive phase 2 data for OCU410 in geographic atrophy. Learn what this means for retinal care, regulation, and future gene therapy adoption.
Medical Devices & Diagnostics
Radiopharm Theranostics builds clinical momentum with RAD 101 data that could influence neuro-oncology workflows
Radiopharm Theranostics reports strong RAD 101 interim data in brain metastases imaging. Read expert analysis on clinical impact and regulatory outlook.
Features & Analysis
Academic partnerships signal Propanc Biopharma, Inc. push into aging biology and tumor resistance science
Propanc Biopharma expands Spanish research alliances ahead of first human oncology trials. Discover what this means for PRP development and strategy.
Pharma & Biotech
Biocatalysis integration deal between SK pharmteco and Prozomix highlights greener pharma production shift
SK pharmteco partners with Prozomix to expand biocatalysis in drug manufacturing. Discover what this means for greener APIs and global CDMO strategy.
Pharma & Biotech
Amani Therapeutics bets $25m on expanding clozapine access in schizophrenia
Amani Therapeutics raises $25M to advance AM-01, a fixed-dose clozapine combination targeting neutropenia. Analysis of what changes — and what risks remain.
Medical Devices & Diagnostics
What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading
Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer's and Parkinson's research. Read the analysis.